STOCK TITAN

IONIS (IONS) insider files to sell 437 shares on Nasdaq

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Insider notice to sell common stock: A Form 144 filing shows proposed sale of 437 shares of common stock on 10/06/2025 via Stifel Nicolaus & Company on Nasdaq with an aggregate market value of $30,268.00. The shares were acquired under an Employee Stock Purchase Plan on 09/03/2024 and paid in cash. The filer represents no undisclosed material adverse information and the filing includes prior sales by the same person totaling 208,648 shares across dates in 2025 with gross proceeds shown (largest single prior sale: $12,228,840.00 on 09/03/2025). The notice states standard Rule 144 and Rule 10b5-1 remarks and signature attestation.

Positive

  • Securities were acquired under an Employee Stock Purchase Plan, indicating lawful, compensation-based acquisition
  • Broker and exchange identified (Stifel Nicolaus & Company; Nasdaq), providing execution transparency

Negative

  • Substantial prior sales in 2025 by the same person (totaling 208,648 shares) could reduce insider ownership
  • Current filing discloses planned sale, which may modestly increase public float if executed

Insights

TL;DR: An insider plans a small planned sale; prior large sales occurred earlier in 2025.

The filing documents a proposed sale of 437 shares acquired under an Employee Stock Purchase Plan on 09/03/2024

Prior sales by the same person show materially larger disposals in 2025 (e.g., $12,228,840.00 on 09/03/2025), which is relevant for liquidity and insider ownership trends. Monitor filings for cumulative insider sell volumes over the next 30–90 days to assess change in beneficial ownership.

TL;DR: Form 144 mechanics and attestations are routine but trigger public disclosure obligations.

The notice lists broker details (Stifel Nicolaus & Company) and the Nasdaq execution venue, and includes the required attestation that no undisclosed material adverse information exists. This is a standard compliance step for shares exceeding Rule 144 thresholds or when particular conditions apply.

Key compliance items to watch: whether an announced sale completes on 10/06/2025 and whether a Rule 10b5-1 plan date appears in subsequent filings, which would affect interpretation of trading intent.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for IONS disclose about the proposed sale?

The filing shows a proposed sale of 437 common shares on 10/06/2025 via Stifel Nicolaus & Company on Nasdaq with aggregate market value $30,268.00.

How were the 437 shares acquired according to the filing for IONS?

The shares were acquired on 09/03/2024 under an Employee Stock Purchase Plan and paid for in cash.

Does the Form 144 include prior sales by the same person for IONS?

Yes; prior sales in 2025 total 208,648 shares with listed gross proceeds including $12,228,840.00 on 09/03/2025.

Who is the executing broker named in the IONS Form 144?

The broker listed is Stifel Nicolaus & Company Inc at the St. Louis address provided in the filing.

Does the filer make any attestation in the Form 144 for IONS?

Yes; the filer represents they do not possess undisclosed material adverse information and includes the standard signature attestation required by Rule 144.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.81B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD